Literature DB >> 18270255

Erectile dysfunction in patients with hyper- and hypothyroidism: how common and should we treat?

Gerasimos E Krassas1, Kostas Tziomalos, Fotini Papadopoulou, Nikolaos Pontikides, Petros Perros.   

Abstract

CONTEXT: Erectile dysfunction (ED) is associated with numerous diseases and aging.
OBJECTIVE: The objective of the study was to investigate the impact of hyper- and hypothyroidism on male sexual health by using the Sexual Health Inventory for Males (SHIM).
DESIGN: Seventy-one men, 27 hyper- and 44 hypothyroid and a similar number of controls were included in the study. A validated SHIM 5-item questionnaire was administered to all participants. Patients were asked to respond before and a year after initiation of treatment for thyroid dysfunction. A score between 25 and 22 is considered normal, between 21 and 11 diagnostic of mild to moderately severe ED, and 10 or less diagnostic of severe ED.
RESULTS: Fifty-six men with thyroid dysfunction (78.9%; 19 hyperthyroid and 37 hypothyroid) had a SHIM score of 21 or less, compared with 24 controls (33.8%) (P < 0.0001). Twenty-one patients with ED (37.5%) had SHIM scores 10 or less, indicative of severe ED, compared with six controls (25%) (P < 0.01). ED was more prevalent in patients with hyperthyroidism and hypothyroidism, compared with controls (P < 0.001 and P < 0.0001, respectively). Positive correlation was found between SHIM scores and serum free T(4) (r = 0.413, P = 0.005) and negative for TSH (r = -0.669, P < 0.001). After treatment a significant increase of SHIM scores was noted in both hyperthyroid (P < 0.0001) and hypothyroid (P < 0.0001) patients.
CONCLUSIONS: ED is extremely common in males with dysthyroidism. Treatment of the latter restores erectile function. Screening for thyroid dysfunction in men presenting with ED is recommended, whereas specific treatment for ED should be postponed in such patients for at least 6 months after achieving euthyroidism because the latter might be responsible for ED.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18270255     DOI: 10.1210/jc.2007-2259

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

1.  [Update hyperthyreoidism].

Authors:  L Möller; K Mann
Journal:  Internist (Berl)       Date:  2010-05       Impact factor: 0.743

Review 2.  Hormonal control of Sertoli cell metabolism regulates spermatogenesis.

Authors:  Marco G Alves; Luís Rato; Rui A Carvalho; Paula I Moreira; Sílvia Socorro; Pedro F Oliveira
Journal:  Cell Mol Life Sci       Date:  2012-07-20       Impact factor: 9.261

3.  Effects of hyperthyroidism, hypothyroidism, and thyroid autoimmunity on female sexual function.

Authors:  A Oppo; E Franceschi; F Atzeni; A Taberlet; S Mariotti
Journal:  J Endocrinol Invest       Date:  2011-04-28       Impact factor: 4.256

Review 4.  [Primary and secondary prevention of erectile dysfunction].

Authors:  A Kaminsky; H Sperling; G Popken
Journal:  Urologe A       Date:  2011-10       Impact factor: 0.639

5.  Triiodothyronine differentially modulates the LH and FSH synthesis and secretion in male rats.

Authors:  Renata Marino Romano; Paula Bargi-Souza; Erika Lia Brunetto; Francemilson Goulart-Silva; Renato M Salgado; Telma Maria Tenorio Zorn; Maria Tereza Nunes
Journal:  Endocrine       Date:  2017-12-05       Impact factor: 3.633

Review 6.  The emerging role of aldosterone/mineralocorticoid receptors in the pathogenesis of erectile dysfunction.

Authors:  Fei Wu; Yun Lin; Qingyong Liu
Journal:  Endocrine       Date:  2018-05-02       Impact factor: 3.633

7.  Fourth revolution in psychiatry - Addressing comorbidity with chronic physical disorders.

Authors:  Shiv Gautam
Journal:  Indian J Psychiatry       Date:  2010-07       Impact factor: 1.759

8.  Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.

Authors:  Sarah L Kerns; Chunkit Fung; Patrick O Monahan; Shirin Ardeshir-Rouhani-Fard; Mohammad I Abu Zaid; AnnaLynn M Williams; Timothy E Stump; Howard D Sesso; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair Beard; Robert A Huddart; Jeri Kim; Christian Kollmannsberger; Deepak M Sahasrabudhe; Ryan Cook; Sophie D Fossa; Lawrence H Einhorn; Lois B Travis
Journal:  J Clin Oncol       Date:  2018-04-04       Impact factor: 44.544

9.  Elevated plasma aldosterone is an independent risk factor for erectile dysfunction in men.

Authors:  Fei Wu; Shanhua Mao; Tianfang Yu; Haowen Jiang; Qiang Ding; Gang Xu
Journal:  World J Urol       Date:  2015-11-02       Impact factor: 4.226

Review 10.  Endocrine evaluation of erectile dysfunction.

Authors:  Andrea Sansone; Francesco Romanelli; Daniele Gianfrilli; Andrea Lenzi
Journal:  Endocrine       Date:  2014-04-06       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.